SEC Form 4 · accession 0001193125-26-304815

Vivos Therapeutics, Inc. · VVOS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jun 30, 2026

Accepted (ET)

Jul 15, 2026 · 4:23 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001716166

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F2,F1	$0.456	Jun 30, 2026	P	859,166	A	—	—	Common Stock	859,166	859,166	I
Series A Convertible Preferred Stock^F3,F2,F1	$0.456	Jun 30, 2026	P	1,890,164	A	—	—	Common Stock	1,890,164	2,749,330	I
Common Stock Purchase Warrant^F2	$0.456	Jun 30, 2026	P	2,749,330	A	Jun 30, 2026	Jun 30, 2031	Common Stock	2,749,330	2,749,330	I

F1The convertible preferred stock is convertible at any time, at the holder's election, subject to a beneficial ownership limitation, and has no expiration date.
F2Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 4 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.
F3On June 30, 2026, V-Co Investors 4 LLC converted a bridge promissory note in the amount of $1,000,000 entered into between the reporting person and the Issuer into shares of the Issuer's Series A Convertible Preferred Stock, based on $0.456 per share plus $0.125 per share in accordance with the Nasdaq minimum price rules.